Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation (ROXI-EVEREST)
A Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention With REGN7508, a Monoclonal Antibody Against Factor XI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-EVEREST)
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban. The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.
The aim of the study is to see how safe and effective REGN7508 is in preventing stroke and/or systemic embolism in participants with atrial fibrillation and how it compares against participants that will receive apixaban in this study.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Clinical Trials Administrator
- 电话号码:844-734-6643
- 邮箱:clinicaltrials@regeneron.com
学习地点
-
-
-
Longueuil、加拿大、J4H4B9
- 招聘中
- Viacar Recherches Cliniques inc.
-
-
Ontario
-
Hamilton、Ontario、加拿大、L8L 5G4
- 招聘中
- Premiere Clinical Trial Network
-
-
Quebec
-
Sherbrooke、Quebec、加拿大、J1LOK3
- 招聘中
- Diex Recherche Inc.
-
-
-
-
Hokkaido
-
Sapporo、Hokkaido、日本、062-0003
- 招聘中
- Hanaoka Seishu Memorial Hospital
-
-
Hyōgo
-
Kawanishi、Hyōgo、日本、666-0125
- 招聘中
- The Veritas Hospital
-
-
Ibaraki
-
Higashiibaraki District、Ibaraki、日本、311-3193
- 招聘中
- National Hospital Organization Mito Medical Center
-
Tsuchiura、Ibaraki、日本、300-8585
- 招聘中
- National Hospital Organization Kasumigaura Medical Center
-
-
Kanagawa
-
Yokohama、Kanagawa、日本、234-0054
- 招聘中
- Saiseikai Yokohama-shi Nanbu Hospital
-
-
Kyoto
-
Kyoto、Kyoto、日本、607-8062
- 招聘中
- Rakuwakai Otowa Hospital
-
-
Yokohama-shi
-
Kanagawa、Yokohama-shi、日本、247-0005
- 招聘中
- JA Tsuchiura Kyodo General Hospital
-
-
-
-
Alabama
-
Alexander City、Alabama、美国、35010
- 招聘中
- Advanced Cardiovascular
-
Dothan、Alabama、美国、36305
- 招聘中
- SEC Clinical Research
-
Fairhope、Alabama、美国、36532
- 招聘中
- Eastern Shore Research Institute
-
-
Arizona
-
Glendale、Arizona、美国、85306
- 招聘中
- West Valley Clinical Trials
-
Scottsdale、Arizona、美国、85260
- 招聘中
- Scottsdale Clinical Trials
-
-
Arkansas
-
Little Rock、Arkansas、美国、72205
- 招聘中
- Arkansas Cardiology P.A.
-
-
California
-
Covina、California、美国、91723
- 招聘中
- Valley Clinical Trials, Inc
-
Fremont、California、美国、94538
- 招聘中
- Mission Cardiovascular Research Institute
-
Huntington Beach、California、美国、92648
- 招聘中
- National Institute of California Heart and Vein Specialists
-
Inglewood、California、美国、90301
- 招聘中
- Alliance Clinical Los Angeles
-
La Jolla、California、美国、92037
- 招聘中
- Profound Research LLC at San Diego Cardiovascular Associates
-
Newport Beach、California、美国、92663
- 招聘中
- Radin Cardiovascular Medical Group
-
Northridge、California、美国、91325
- 招聘中
- Valley Clinical Trials, LLC dba Flourish Research
-
Pasadena、California、美国、91105
- 招聘中
- Southern California Heart Specialists
-
Santa Maria、California、美国、93454
- 招聘中
- FOMAT - Comprehensive Cardiovascular Care
-
Ventura、California、美国、93003
- 招聘中
- Cardiology Associates Medical Group
-
West Hills、California、美国、91307
- 招聘中
- Interventional Cardiology Medical Group
-
-
Florida
-
Boca Raton、Florida、美国、33434
- 招聘中
- Excel Medical Clinical Trials, dba Flourish Research
-
Cutler Bay、Florida、美国、33189
- 招聘中
- Nouvelle Clinical Research LLC
-
Inverness、Florida、美国、34452
- 招聘中
- Nature Coast Clinical Research - Inverness
-
Medley、Florida、美国、33166
- 招聘中
- South Florida Research Organization LLC
-
New Smyrna Beach、Florida、美国、32168
- 招聘中
- Healix Clinical Research
-
Pensacola、Florida、美国、32503
- 招聘中
- Sec Clinical Research
-
Saint Augustine、Florida、美国、32086
- 招聘中
- Flourish Research, St. Johns Center for Clinical Research
-
Sarasota、Florida、美国、34239
- 招聘中
- Cardiovascular Center of Sarasota Foundation for Research and Education
-
Winter Park、Florida、美国、32789
- 招聘中
- Clinical Site Partners, LLC DBA Flourish Research
-
-
Georgia
-
Atlanta、Georgia、美国、30342
- 招聘中
- Atlanta Clinical Research Centers
-
Atlanta、Georgia、美国、30310
- 招聘中
- Morehouse School Of Medicine
-
Johns Creek、Georgia、美国、30024
- 招聘中
- NSC Research, Inc
-
-
Indiana
-
Hobart、Indiana、美国、46342
- 招聘中
- Profound Research, Advanced Cardiovascular Care + Electrophysiology Clinic
-
Munster、Indiana、美国、46321
- 招聘中
- Profound Research, Powers Health Medical Group - Electrophysiology
-
Munster、Indiana、美国、46321-4054
- 招聘中
- Cardiovascular Research of Northwest Indiana, LLC
-
-
Louisiana
-
West Monroe、Louisiana、美国、71291
- 招聘中
- Monroe Research, LLC
-
-
Maryland
-
Ft. Washington、Maryland、美国、20744
- 招聘中
- Anderson Medical Research
-
-
Massachusetts
-
Foxborough、Massachusetts、美国、02035
- 招聘中
- K2 Medical Research, Foxboro
-
-
Michigan
-
Bloomfield Hills、Michigan、美国、48304
- 招聘中
- Profound Research, Cardiology and Vascular Associates (CAVA) - Bloomfield Hills
-
Farmington Hills、Michigan、美国、48334
- 招聘中
- Profound Research, Millennium Cardiology
-
Flint、Michigan、美国、48503
- 招聘中
- Flint Clinical Research
-
-
New York
-
Staten Island、New York、美国、10309
- 招聘中
- Super Health Pharmacy
-
-
North Carolina
-
Concord、North Carolina、美国、28025
- 招聘中
- Hawthorne Health, Moose Pharmacy of Concord
-
High Point、North Carolina、美国、27260
- 招聘中
- Peters Medical Research
-
-
North Dakota
-
Fargo、North Dakota、美国、58104
- 招聘中
- Lillestol Research LLC
-
-
Ohio
-
Marion、Ohio、美国、43302
- 招聘中
- K&R Research LLC
-
Maumee、Ohio、美国、43537
- 招聘中
- Advanced Medical Research
-
-
South Dakota
-
Rapid City、South Dakota、美国、57701
- 招聘中
- Monument Health Clinical Research
-
-
Tennessee
-
Tullahoma、Tennessee、美国、37388
- 招聘中
- Tennessee Center for Clinical Trials
-
-
Texas
-
Amarillo、Texas、美国、79106
- 招聘中
- PharmaTex Research
-
Brownsville、Texas、美国、78520
- 招聘中
- PanAmerican Clinical Research
-
Houston、Texas、美国、77061
- 招聘中
- Synergy Groups Medical
-
Houston、Texas、美国、77094
- 招聘中
- West Houston Area Clinical Trial Consultants, LLC
-
Missouri City、Texas、美国、77459
- 招聘中
- Synergy Group Medical, LLC
-
Odessa、Texas、美国、79761
- 招聘中
- Permian Research Foundation
-
Tyler、Texas、美国、75701
- 招聘中
- Tyler Cardiovascular Consultants
-
-
Utah
-
Clinton、Utah、美国、84015
- 招聘中
- Alpine Research TC
-
-
Virginia
-
Manassas、Virginia、美国、20109
- 招聘中
- Carient Heart & Vascular
-
Vienna、Virginia、美国、22182
- 招聘中
- Conquest Research
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
-
Has AF or flutter (paroxysmal or persistent), not considered to be secondary to a reversible cause, and an indication for indefinite anticoagulation treatment as described in the protocol
-
Meets one of the following:
- CHA2DS2-VA [C: Congestive heart failure; H: Hypertension; A2: Age ≥75 years (double points); D: Diabetes mellitus; S2: Stroke or TIA or Systemic embolism (double points); V: Vascular disease; A: Age 65-74 years] score ≥2 and Oral Anticoagulant (OAC) naïve OR
- CHA2DS2-VA score ≥3 OR
- CHA2DS2-VA score of 2 AND at least 1 enrichment criteria as described in the protocol
-
Must have an International Normalized Ratio (INR) <2.5 at the time of randomization if taking warfarin or another Vitamin K Antagonist (VKA)
Key Exclusion Criteria:
- Has a mechanical heart valve prosthesis (Note: transcatheter aortic valve replacement is not an exclusion)
- Has known moderate-to-severe mitral stenosis
- Has had a successful ablation therapy without documented recurrent AF or a participant after Left Atrial Appendage (LAA) occlusion/exclusion or plan for ablation or LAA occlusion/exclusion within the next 6 months starting from randomization
- Had an ischemic stroke within 2 days prior to randomization
- Has persistent, uncontrolled hypertension (per investigator's discretion)
- Has estimated Glomerular Filtration Rate (eGFR) <15 mL/min/1.73m2 within 30 days prior to randomization or is on dialysis or expected to be started on dialysis within the next 6 months starting from randomization
Note: Other protocol-defined Inclusion/ Exclusion criteria apply
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:REGN7508 + Placebo
|
Administered per the protocol Administered per the protocol
其他名称:
|
|
有源比较器:Apixaban + Placebo
|
Administered per the protocol Administered per the protocol |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type) or systemic embolism
大体时间:Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding or ISTH Clinically Relevant Non-Major (CRNM) bleeding
大体时间:Approximately 36 months
|
Approximately 36 months
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, ISTH major bleeding, or ISTH CRNM bleeding
大体时间:Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, or ISTH major bleeding
大体时间:Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, ISTH major bleeding, or all-cause death
大体时间:Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of ISTH major bleeding
大体时间:Approximately 36 months
|
Approximately 36 months
|
|
Time to first occurrence of hemorrhagic stroke, intracerebral hemorrhage, or hemorrhagic transformation of an ischemic stroke
大体时间:Approximately 36 months
|
Approximately 36 months
|
|
Time to occurrence of fatal bleeding
大体时间:Approximately 36 months
|
Approximately 36 months
|
|
Number of ISTH major bleeding events
大体时间:Approximately 36 months
|
Approximately 36 months
|
|
Number of ISTH CRNM bleeding events
大体时间:Approximately 36 months
|
Approximately 36 months
|
|
Number of minor bleeding events
大体时间:Approximately 36 months
|
Approximately 36 months
|
|
Time to all-cause death
大体时间:Approximately 36 months
|
Approximately 36 months
|
|
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
大体时间:Approximately 39 months
|
Approximately 39 months
|
|
Severity of TEAEs
大体时间:Approximately 39 months
|
Approximately 39 months
|
|
Occurrence of Anti-Drug Antibodies (ADA) to REGN7508
大体时间:Approximately 36 months
|
Approximately 36 months
|
|
Magnitude of ADA to REGN7508
大体时间:Approximately 36 months
|
Approximately 36 months
|
合作者和调查者
调查人员
- 研究主任:Clinical Trial Management、Regeneron Pharmaceuticals
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- R7508-CVA-24114
- 2025-521617-97-00 (克蒂斯)
- 2025 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD 共享时间框架
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD 共享访问标准
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 分析代码
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.